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Introduction
Myasthenia gravis (MG) is a chronic
autoimmune neuromuscular disease
characterized by ocular, bulbar, facial,
and skeletal muscle weakness due to a
defect in the transmission of nerve to
muscle impulses at the neuromuscular
junction (Mestecky, 2013, p. 110).
Approximately 14-20 in 100,000
people are diagnosed with myasthenia
gravis in the United States (Leis, Moore,
Kofler, Beric, De Visser, 2014, p. 112).
Typically, diagnosis occurs in middleaged adults with women generally
acquiring the disease at a younger age
than men (Mestecky, 2013, p. 110). MG
has the potential to greatly affect the
quality of life of a patient.
Although the disease may go into
remission for any given amount of time,
there is currently no known cure for
myasthenia gravis. Patients experience
varying degrees of symptoms, however,
there are several treatment options
available to help those with MG decrease
symptoms and lead full lives.

MG is an uncommon disease that
can greatly affect the lives of the
patient and their family members.
Patients may experience myasthenic
crisis, which is life threatening,
however, it is important to remember
that they continue living with the
disease and its effects every day.
Family Nurse Practitioners must
design an individualized care plan to
treat and manage symptoms in a
patient’s every day life. It is also
imperative to note that official
diagnosis of MG may be delayed in
many patients because the symptoms
vary in each case. It is important to
have a solid knowledge base regarding
this disease in order to adequately
diagnose patients in a timely manner.
This is a manageable disease but can
become life threatening, therefore,
earlier recognition and treatment is
essential.

Signs & Symptoms
Bulbar Symptoms:
•
Eye muscle weakness
•
Ptosis, double vision, blurring
•
Slurred speech
•
Stuttering
•
Low endurance of mastication
•
Droop of corners of mouth
•
Facial weakness/droop
•
Dysphagia
Trunk/Limb Symptoms:
•
Proximal symptoms
•
Weak neck muscles: head drooping
•
Arms, shoulder weakness
•
Wrist, finger weakness
•
Ankle weakness

The hallmark sign of MG is fluctuating
muscle weakness and fatigue that is
exacerbated with activity and improves with
rest. Weakness is typically least
bothersome in the morning, when
acetylcholine stores are highest, and
symptoms worsen as the day progresses
(Abbott, 2010, p. 471).

Conclusion

Underlying Pathophysiology

Significance
In a normally functioning
neuromuscular system, transmission of nerve
impulses to the muscle occurs at the
neuromuscular junction (NMJ). The
neurotransmitter acetylcholine is released
from the motor neurons, crosses the synaptic
cleft, and attaches to the acetylcholine
receptor on the muscle fibers, consequently
generating a muscle contraction. This
mechanism is altered in patients with
myasthenia gravis.
Myasthenia gravis is a relatively rare,
autoimmune, neuromuscular disorder. “MG is
a B-cell driven, T-cell dependent, complement
and antibody-mediated disease, due to
autoantibodies directed against molecules at
the neuromuscular junction” (Avidan, Panse,
Berrih-Aknin, Miller, 2014, p. 146). These

antibodies are directed against proteins
concentrated at the NMJ, which include
nicotinic acetylcholine receptor (AChR), the
muscle-specific kinase (MuSK), or the
lipoprotein-related protein 4 (LRP4). The
most common antibody found in MG patients
is against AChR (Kusner, Ciesielski, Marx,
Kaminski, Fenstermaker, 2014, p. 1). “The
binding of anti-AChR antibodies to their target
impairs neuromuscular transmission by
complement-mediated destruction of the
postsynaptic membrane” (Avidan et al., 2014,
p. 146).
The thymus gland is the chief organ for
immunological self-tolerance and usually
decreases in size and is replaced with fat as
one ages (Weeks, 2012, p. 31). Many patients
with MG have thymus abnormalities including

Myasthenia gravis was once an
unknown neurological disease with poor
outcomes. However, with continuous
advanced research, it is now one of the
most understood autoimmune diseases
today. Although it is still a serious
condition, patients with this diagnosis are
expected to have longer survival rates and
increased quality of daily life activities.
Nurse practitioners are providers that will
have contact with these patients very
frequently and keen assessment skills are
needed for accurate diagnosis. Continuous
research and treatment plans may lead to
not only longer periods of remission, but
possibly a cure.

hyperplasia or thymoma, which may play a
role in disease initiation. These mechanisms
include the expression of self-antigens by
thymoma cells and impairment of
autoreactive T lymphocytes (Ha & Richman,
2014, p. 652). The exact role of thymus in MG
is not fully understood, however, researchers
suspect that viruses or bacteria may trigger
this autoimmune response.
Patients with MG experience cycles of
remission and exacerbation. There are many
factors thought to exacerbate the symptoms
associated with MG. These include pregnancy,
emotional stress, thyroid disease,
menstruation cycle, and viral or bacterial
illness particularly upper respiratory
infection (Abbott, 2010, p. 470).

Significance of Pathophysiology
The estimated amount of MG patients
has more than doubled in the last twenty
years (Avidan et al., 2014, p. 146). This
could be because of many factors including
better diagnosis, improved treatment, and
an increasing aging population. The
average age of onset for females is 20-30
years; the average age of onset for males is
60-80 years. This is significant information
to consider because of the increasing aging
population. It is probable that because
people are living longer, there is an increase
in the amount of people experiencing the
onset of MG.
Although there is plenty still unknown,
MG is considered to be one of the best
understood of all autoimmune diseases.
Before improved corticosteroid therapies
were developed, one third of patients
diagnosed with myasthenia gravis died
(Abbott, 2010, p. 470). With continued
improvements in research, diagnosis, and
treatment the prognosis is good in terms of
quality of life, daily functions, and survival
(Sieb, 2013, p. 408).
Understanding the pathophysiology is
of extreme importance so diagnosis is
completed quicker and more accurately,
and treatment options are performed. As
mentioned previously, it is now known that
MG can be divided into subcategories of
antibody specificity. Understanding exactly
where and how the antibodies are impeding
function at the NMJ leads to more accurate
treatment options and prolonged periods of
remission.
Knowing the significance of
pathophysiology of MG is crucial because
these patients are susceptible to myasthenic

crisis, a life threatening condition. During
myasthenic crisis, the respiratory and
accessory muscles are significantly
weakened as well as the diaphragm (Weeks,
2012, p. 33). These patients often require a
mechanical ventilator until the exacerbation
subsides. Although a critical condition, with
improvements in knowledge about the
disease and proper treatments, mortality
from myasthenic crisis alone is less than
5% (Weeks, 2012, p. 32).
Qualitative research also assists in
understanding the significance of the
disease process. “Incorporating the
patient’s perspective provides invaluable
information regarding which impairments
are most relevant to patients as well as
patterns of impairment” (Barnett, Bril,
Kapral, Kulkarni, Davis, 2014, p. 1). A
patient may verbalize difficulty with daily
activities due to weakness but may have a
one time clinical presentation displaying the
opposite. Concerning MG, this is the
hallmark sign of fatigability. A solid
knowledge base of the pathological
processes taking place will only enhance the
understanding of the patient’s perspective
of symptoms, thus, leading to better
treatment and care plans.

Implications for Nursing Care
The highly variable symptom presentation of
myasthenia gravis can pose considerable challenges
to accurate diagnosis. Because of the similarities of
symptoms with many other neurological diseases
and disorders, providers may unknowingly give a
wrong diagnosis. Physical examination, thorough
neurological assessment, and detailed medical
history are of utmost important. Providers, such as
nurse practitioners, must have a substantial
understanding of MG and its presentation in order to
differentiate other diagnoses. It is now becoming
possible to identify the antigenic target in almost all
cases of MG, consequently leading to more specific
care plans and focused therapies (Lewis, 2013, p.
97). The earlier MG is recognized and treatment
started, the better the outcomes and quality of life for

the patient.
Education plays a
huge role in nursing care for those affected by MG.
Knowing the disease process, how it affects ones
body, and ways to improve or avoid symptoms is of
utmost importance. Nursing care plays a primary
role in educating patients on how to enhance their
daily lives while living with a chronic condition.
Because of the increase in diagnosis and aging
population as previously stated, providers are highly
likely to come in contact with a patient diagnosed
with MG during their career. Understanding the
pathophysiology as well as the patient’s perception of
the disease and its symptoms will only serve to
improve overall care and clinical decision-making.
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